Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma.
Ebisudani T, Hamamoto J, Togasaki K, Mitsuishi A, Sugihara K, Shinozaki T, Fukushima T, Kawasaki K, Seino T, Oda M, Hanyu H, Toshimitsu K, Emoto K, Hayashi Y, Asakura K, Johnson TA, Terai H, Ikemura S, Kawada I, Ishii M, Hishida T, Asamura H, Soejima K, Nakagawa H, Fujii M, Fukunaga K, Yasuda H, Sato T. Ebisudani T, et al. Among authors: terai h. Cell Rep. 2023 Mar 28;42(3):112212. doi: 10.1016/j.celrep.2023.112212. Epub 2023 Mar 6. Cell Rep. 2023. PMID: 36870059 Free article.
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. Nakachi I, et al. Among authors: terai h. Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20. Mol Cancer Res. 2010. PMID: 20647329
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S, Soejima K, Yasuda H, Naoki K, Kawada I, Watanabe H, Nakachi I, Satomi R, Nakayama S, Ikemura S, Terai H, Sato T, Morosawa M, Asano K. Yoda S, et al. Among authors: terai h. Cancer Chemother Pharmacol. 2011 Mar;67(3):717-22. doi: 10.1007/s00280-010-1539-y. Epub 2010 Dec 9. Cancer Chemother Pharmacol. 2011. PMID: 21152917 Clinical Trial.
The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing.
Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, Nakachi I, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Watanabe K. Naoki K, et al. Among authors: terai h. Int J Clin Oncol. 2011 Aug;16(4):335-44. doi: 10.1007/s10147-011-0187-5. Epub 2011 Feb 11. Int J Clin Oncol. 2011. PMID: 21311943
462 results